PL2438087T3 - Triwalentne konstrukty nanociał przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (hRSV) do zapobiegania i/lub leczenia zakażeń dróg oddechowych - Google Patents

Triwalentne konstrukty nanociał przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (hRSV) do zapobiegania i/lub leczenia zakażeń dróg oddechowych

Info

Publication number
PL2438087T3
PL2438087T3 PL10724497T PL10724497T PL2438087T3 PL 2438087 T3 PL2438087 T3 PL 2438087T3 PL 10724497 T PL10724497 T PL 10724497T PL 10724497 T PL10724497 T PL 10724497T PL 2438087 T3 PL2438087 T3 PL 2438087T3
Authority
PL
Poland
Prior art keywords
hrsv
prevention
treatment
syncytial virus
tract infections
Prior art date
Application number
PL10724497T
Other languages
English (en)
Inventor
Erik Depla
Catelijne Stortelers
Stephanie Staelens
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of PL2438087T3 publication Critical patent/PL2438087T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10724497T 2009-06-05 2010-06-07 Triwalentne konstrukty nanociał przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (hRSV) do zapobiegania i/lub leczenia zakażeń dróg oddechowych PL2438087T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18439609P 2009-06-05 2009-06-05
US26501409P 2009-11-30 2009-11-30
EP10724497.2A EP2438087B1 (en) 2009-06-05 2010-06-07 Trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
PCT/EP2010/057921 WO2010139808A2 (en) 2009-06-05 2010-06-07 IMPROVED AMINO ACID SEQUENCES DIRECTED AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (hRSV) AND POLYPEPTIDES COMPRISING THE SAME FOR THE PREVENTION AND/OR TREATMENT OF RESPIRATORY TRACT INFECTIONS

Publications (1)

Publication Number Publication Date
PL2438087T3 true PL2438087T3 (pl) 2017-10-31

Family

ID=42333502

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10724497T PL2438087T3 (pl) 2009-06-05 2010-06-07 Triwalentne konstrukty nanociał przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (hRSV) do zapobiegania i/lub leczenia zakażeń dróg oddechowych

Country Status (25)

Country Link
US (3) US8945567B2 (pl)
EP (2) EP3205670A1 (pl)
JP (2) JP6081196B2 (pl)
KR (1) KR101852204B1 (pl)
CN (2) CN105061592A (pl)
AU (1) AU2010255638B2 (pl)
BR (1) BRPI1010830A2 (pl)
CA (1) CA2764398A1 (pl)
CY (1) CY1119265T1 (pl)
DK (1) DK2438087T3 (pl)
ES (1) ES2643034T3 (pl)
HR (1) HRP20171194T1 (pl)
HU (1) HUE035773T2 (pl)
IL (1) IL216341A0 (pl)
LT (1) LT2438087T (pl)
MX (1) MX340541B (pl)
NZ (1) NZ597314A (pl)
PH (1) PH12019500644A1 (pl)
PL (1) PL2438087T3 (pl)
PT (1) PT2438087T (pl)
RU (2) RU2577134C2 (pl)
SG (1) SG176095A1 (pl)
SI (1) SI2438087T1 (pl)
WO (1) WO2010139808A2 (pl)
ZA (1) ZA201108892B (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2285408T3 (pl) 2008-06-05 2019-05-31 Ablynx Nv Sekwencje aminokwasowe skierowane przeciwko białkom otoczki wirusa i polipeptydy je zawierające do leczenia chorób wirusowych
LT2438087T (lt) 2009-06-05 2017-08-25 Ablynx N.V. Trivalenčiai nanokūno konstruktai prieš žmogaus respiratorinį sincitinį virusą (hrsv), skirti kvėpavimo takų infekcijų profilaktikai ir (arba) gydymui
EP2507262A1 (en) * 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
HUE044292T2 (hu) 2010-02-11 2019-10-28 Ablynx Nv Eljárások és készítmények aeroszolok elõállítására
EP2632946B1 (en) 2010-10-29 2017-12-06 Ablynx N.V. Method for the production of immunoglobulin single variable domains
US9534039B2 (en) 2011-05-09 2017-01-03 Ablynx N.V. Method for the production of immunoglobulin single variable domains
US11339208B1 (en) 2012-05-31 2022-05-24 United States Of America As Represented By The Secretary Of The Air Force Camelidae single-domain antibodies against Yersinia pestis and methods of use
SI2968520T1 (sl) 2013-03-14 2022-01-31 Macrogenics, Inc. Bispecifične molekule, ki so imunoreaktivne z imunskimi efektorskimi celicami, ki izražajo aktivacijski receptor
PE20160547A1 (es) 2013-08-21 2016-06-19 Alios Biopharma Inc Compuestos antivirales
US20160045528A1 (en) * 2014-08-05 2016-02-18 Alios Biopharma, Inc. Combination therapy for treating a paramyxovirus
CN107108721B (zh) 2014-09-29 2021-09-07 杜克大学 包含hiv-1包膜靶向臂的双特异性分子
TR201909589T4 (tr) 2014-10-10 2019-07-22 Ablynx Nv Solunum hastalıklarının aerosol terapisinde kullanıma yönelik inhalasyon cihazı.
CN107206069A (zh) * 2014-10-10 2017-09-26 埃博灵克斯股份有限公司 Rsv感染的治疗
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
MX2017016590A (es) * 2015-06-18 2018-11-09 Vib Vzw Dominios variables simples de inmunoglobulina contra proteina f de rsv.
EP3124042A1 (en) * 2015-07-28 2017-02-01 VIB, vzw Immunoglobulin single variable domain antibody against rsv prefusion f protein
CN109311968A (zh) 2016-05-02 2019-02-05 埃博灵克斯股份有限公司 治疗rsv感染
US20190195866A1 (en) 2016-06-23 2019-06-27 Ablynx N.V. Improved pharmacokinetic assays for immunoglobulin single variable domains
CN106279410B (zh) * 2016-09-29 2019-08-20 华南理工大学 一种二型登革热病毒ns1蛋白多价纳米抗体及制备方法
JP2020503843A (ja) 2016-10-21 2020-02-06 アディマブ， エルエルシー 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP7265984B2 (ja) 2016-10-21 2023-04-27 アディマブ， エルエルシー 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
US11312761B2 (en) 2016-10-21 2022-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
CA3075510A1 (en) 2017-10-13 2019-04-18 Adimab, Llc Anti-respiratory syncytial virus antibodies, methods of their generation and use
JP7123607B2 (ja) * 2018-04-09 2022-08-23 シャープ株式会社 ユーザ装置、制御装置、及び通信制御方法
US20220185900A1 (en) 2019-04-10 2022-06-16 Regeneron Pharmaceuticals, Inc. Human antibodies that bind ret and methods of use thereof
CN111748571B (zh) * 2019-10-11 2022-05-03 浙江禾霖生物科技有限公司 一种将枯草芽孢杆菌工程化为生产纳米抗体的多功能稳定平台的方法
CA3162718A1 (en) 2019-11-25 2021-06-03 Mabloc, Llc Anti-yellow fever virus antibodies, and methods of their generation and use
US20210230248A1 (en) * 2020-01-25 2021-07-29 Jun Chen Multivalent pharmacophores for high avidity and overexpressed-target specific binding and uses thereof
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
CN116693673B (zh) * 2023-07-26 2023-10-20 中国人民解放军军事科学院军事医学研究院 广谱抗SARS和SARS-CoV-2的纳米抗体、多价纳米抗体及其应用

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1120945A (en) 1964-08-11 1968-07-24 Fisons Pharmaceuticals Ltd Applicator in combination with a pressurised aerosol dispensing container
WO1990004788A1 (en) 1988-10-28 1990-05-03 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
JP4251406B2 (ja) 1990-04-05 2009-04-08 クレア，ロベルト ウォーク―スルー突然変異誘発
CA2119930C (en) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production of chimeric antibodies - a combinatorial approach
AU687010B2 (en) 1992-07-17 1998-02-19 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
WO1994004678A1 (en) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulins devoid of light chains
DE69434447T2 (de) 1993-06-07 2006-05-18 Vical, Inc., San Diego Für die gentherapie verwendbare plasmide
JPH08511160A (ja) 1993-06-09 1996-11-26 ユニリーバー・ナームローゼ・ベンノートシャープ 形質転換真カビによってＳｃＦｖフラグメントを含んでなる融合タンパク質を生産する方法
US6091639A (en) 1993-08-27 2000-07-18 Kabushiki Kaisha Toshiba Non-volatile semiconductor memory device and data programming method
JP3810791B2 (ja) 1993-09-10 2006-08-16 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 緑色蛍光タンパク質の使用
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
JPH10501681A (ja) 1994-02-22 1998-02-17 ダナ−ファーバー キャンサー インスティチュート 核酸送達システムならびにその合成および使用方法
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5693492A (en) 1995-05-05 1997-12-02 Merck & Co., Inc. DNA encoding glutamate gated chloride channels
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
WO1997011094A1 (en) 1995-09-22 1997-03-27 Novo Nordisk A/S Novel variants of green fluorescent protein, gfp
US6027881A (en) 1996-05-08 2000-02-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
WO1998019704A1 (en) * 1996-11-01 1998-05-14 Smithkline Beecham Corporation Human monoclonal antibodies
WO1998021355A1 (en) 1996-11-15 1998-05-22 Life Technologies, Inc. Mutants of green fluorescent protein
EP1027073A2 (en) 1996-11-19 2000-08-16 Sangstat Medical Corporation Enhanced effects for hapten conjugated therapeutics
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
FR2766826B1 (fr) 1997-08-04 2001-05-18 Pasteur Institut Vecteurs derives d'anticorps pour le transfert de substances dans les cellules
CN1316910A (zh) 1998-02-19 2001-10-10 埃克斯西特治疗公司 用于调节淋巴细胞活化的组合物及方法
GB9824632D0 (en) 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
WO2000046383A2 (en) 1999-02-05 2000-08-10 Rijksuniversiteit Leiden Method of modulating metabolite biosynthesis in recombinant cells
CN100434441C (zh) 1999-04-22 2008-11-19 荷兰联合利华有限公司 利用单价抗原-结合蛋白抑制病毒感染
AR030019A1 (es) * 1999-05-18 2003-08-13 Smithkline Beecham Corp Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m
WO2001009300A2 (en) 1999-08-02 2001-02-08 Keygene N.V. Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
DE19955408A1 (de) 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
CA2921260A1 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US6741957B1 (en) 2000-07-21 2004-05-25 Daimlerchrysler Corporation Analytical tire model for vehicle durability and ride comfort analysis
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US7054297B1 (en) 2000-12-28 2006-05-30 Cisco Technology, Inc. Distribution of packets to high data rate communications devices using multicast protocols
PL364623A1 (pl) 2001-01-17 2004-12-13 Trubion Pharmaceuticals, Inc. Białka fuzyjne domena wiążąca-immunologlobulina
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
JP4336771B2 (ja) 2001-03-09 2009-09-30 モルフォシス アーゲー 血清アルブミン結合部分
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2002355477B2 (en) 2001-08-03 2008-09-25 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
FR2829940A1 (fr) 2001-09-27 2003-03-28 Synt Em Compositions pour la vectorisation d'anticorps a travers la barriere hematoencephalique et leur utilisation pour le diagnostic ou le traitement des maladies du systeme nerveux central
KR100599789B1 (ko) 2001-12-03 2006-07-12 삼성에스디아이 주식회사 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
CA2468690A1 (en) 2001-12-18 2003-06-26 Innogenetics N.V. Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US7004940B2 (en) 2002-10-10 2006-02-28 Ethicon, Inc. Devices for performing thermal ablation having movable ultrasound transducers
JP2006512910A (ja) 2002-10-23 2006-04-20 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ａ３４およびａ３３様３ｄｎａ、タンパク質、それらに対する抗体、ならびに同一物を使用した治療方法
JP2006519763A (ja) 2002-11-08 2006-08-31 アブリンクス エン．ヴェー． 治療用ポリペプチドの投与法およびそのためのポリペプチド
EP2267032A3 (en) 2002-11-08 2011-11-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
US7432330B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
ES2542330T3 (es) 2003-01-10 2015-08-04 Ablynx N.V. Polipéptidos terapéuticos, homólogos de los mismos, fragmentos de los mismos y su uso en modular la agregación mediada por plaquetas
EP2395016A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
US7070786B2 (en) 2003-06-06 2006-07-04 Centocor, Inc. RSV proteins, antibodies, compositions, methods and uses
US20050136428A1 (en) 2003-06-27 2005-06-23 Roberto Crea Look-through mutagenesis
EP1639465B1 (de) 2003-06-30 2011-04-06 Continental Automotive GmbH Verfahren zur überwachung des programmlaufs in einem mikro-computer
AU2004220325B2 (en) 2003-06-30 2011-05-12 Domantis Limited Polypeptides
WO2005018629A1 (en) 2003-08-12 2005-03-03 Yarbrough William M Treatment for acne vulgaris and method of use
EP1512696A1 (en) 2003-08-14 2005-03-09 Diatos Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
US20050288491A1 (en) 2004-02-17 2005-12-29 Wilson David S Super-humanized antibodies against respiratory syncytial virus
US7207410B2 (en) 2004-04-29 2007-04-24 Daimlerchrysler Corporation Apparatus and method for enhanced impact sensing
NZ582684A (en) 2004-06-18 2011-05-27 Ambrx Inc Use of an antibody or binding fragment thereof comprising a non naturally encoded amino acid coupled to a linker
ES2372503T3 (es) 2004-07-06 2012-01-20 Bioren, Inc. Mutagénesis revisada para desarrollar polipéptidos alterados con propiedades potenciadas.
US7180370B2 (en) 2004-09-01 2007-02-20 Micron Technology, Inc. CMOS amplifiers with frequency compensating capacitors
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
JP2008513540A (ja) 2004-09-21 2008-05-01 メディミューン，インコーポレーテッド 呼吸器合胞体ウイルスに対する抗体及び該ウイルス用のワクチンを製造する方法
BRPI0518151A2 (pt) * 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
TW200636064A (en) * 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
US20060115485A1 (en) 2004-10-29 2006-06-01 Medimmune, Inc. Methods of preventing and treating RSV infections and related conditions
BRPI0518622A2 (pt) * 2004-12-02 2008-12-02 Domantis Ltd usos de antagonistas de receptor do tipo 1 de interleucina-1(il-1r1) para a fabricaÇço de um medicamento para o tratamento de uma doenÇa respiratària; composiÇço farmacÊutica que compreende um antagonista do il-1r1 e um veÍculo fisiologicamente aceitÁvel e dispositivo de liberaÇço de medicamento
CN101484182B (zh) * 2005-04-06 2014-06-11 Ibc药品公司 由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途
AU2006234847A1 (en) 2005-04-08 2006-10-19 Medimmune, Llc Antibodies against mammalian metapneumovirus
PL1888640T3 (pl) 2005-05-18 2012-08-31 Ablynx Nv Ulepszone nanociała skierowane przeciwko czynnikowi martwicy nowotworów typu alfa
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
JP2010502208A (ja) 2006-09-08 2010-01-28 アブリンクス エン．ヴェー． 半減期の長い血清アルブミン結合タンパク質
WO2008043821A1 (en) 2006-10-11 2008-04-17 Ablynx N. V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and use thereof
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
EP2081960B1 (en) 2006-10-27 2018-06-27 Ablynx N.V. Intranasal delivery of polypeptides and proteins
US20080267949A1 (en) 2006-12-05 2008-10-30 Ablynx N.V. Peptides capable of binding to serum proteins
US8906680B2 (en) 2006-12-22 2014-12-09 Ablynx N.V. Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders
JP5240870B2 (ja) 2007-07-03 2013-07-17 アブリンクス エン．ヴェー． 改善した免疫グロブリン配列を提供する方法
CA2706200A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Immunoglobulin constructs comprising multiple single variable domains and an fc portion
EP2096121A1 (en) 2008-02-29 2009-09-02 Institut Pasteur Of Shanghai Antiviral peptides comprising lipid attachment signals and methods of use
PL2285408T3 (pl) 2008-06-05 2019-05-31 Ablynx Nv Sekwencje aminokwasowe skierowane przeciwko białkom otoczki wirusa i polipeptydy je zawierające do leczenia chorób wirusowych
EP2387583B1 (en) 2009-01-14 2018-09-19 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
DK2424889T3 (en) 2009-04-30 2015-11-02 Ablynx Nv Process for the preparation of domain antibodies
LT2438087T (lt) 2009-06-05 2017-08-25 Ablynx N.V. Trivalenčiai nanokūno konstruktai prieš žmogaus respiratorinį sincitinį virusą (hrsv), skirti kvėpavimo takų infekcijų profilaktikai ir (arba) gydymui
EP2507262A1 (en) 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections

Also Published As

Publication number Publication date
DK2438087T3 (en) 2017-08-28
SI2438087T1 (sl) 2017-10-30
PH12019500644A1 (en) 2020-10-12
CN102459332B (zh) 2015-08-19
SG176095A1 (en) 2011-12-29
RU2011153239A (ru) 2013-07-20
JP6081196B2 (ja) 2017-03-01
JP6677659B2 (ja) 2020-04-08
AU2010255638B2 (en) 2014-10-16
KR101852204B1 (ko) 2018-04-26
US20120128669A1 (en) 2012-05-24
HRP20171194T1 (hr) 2017-10-20
RU2016103067A (ru) 2018-11-20
CY1119265T1 (el) 2018-02-14
BRPI1010830A2 (pt) 2023-11-14
EP2438087B1 (en) 2017-05-10
ES2643034T3 (es) 2017-11-21
MX2011013013A (es) 2012-01-30
US20180105581A1 (en) 2018-04-19
JP2012528584A (ja) 2012-11-15
US11028151B2 (en) 2021-06-08
LT2438087T (lt) 2017-08-25
CN102459332A (zh) 2012-05-16
ZA201108892B (en) 2013-05-29
PT2438087T (pt) 2017-08-04
US9803001B2 (en) 2017-10-31
JP2017093460A (ja) 2017-06-01
EP2438087A2 (en) 2012-04-11
HUE035773T2 (en) 2018-05-28
CN105061592A (zh) 2015-11-18
MX340541B (es) 2016-07-13
US8945567B2 (en) 2015-02-03
EP3205670A1 (en) 2017-08-16
RU2577134C2 (ru) 2016-03-10
IL216341A0 (en) 2012-01-31
RU2016103067A3 (pl) 2019-08-08
CA2764398A1 (en) 2010-12-09
WO2010139808A2 (en) 2010-12-09
NZ597314A (en) 2013-07-26
AU2010255638A1 (en) 2012-01-12
WO2010139808A3 (en) 2011-02-24
KR20140015113A (ko) 2014-02-06
US20150118233A1 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
LT2438087T (lt) Trivalenčiai nanokūno konstruktai prieš žmogaus respiratorinį sincitinį virusą (hrsv), skirti kvėpavimo takų infekcijų profilaktikai ir (arba) gydymui
HK1172350A1 (zh) 針對人呼吸道合胞病毒 的抗體以及使用方法
HK1199607A1 (en) Human milk oligosaccharides for preventing injury and or promoting healing of the gastrointestinal tract
HK1196131A1 (zh) 用於治療或預防呼吸道合胞病毒疾病的化合物
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
IL227193B (en) Plant extracts for the treatment and prevention of inflammation
PL2521562T3 (pl) Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych
EP2349140A4 (en) DEVICES, SYSTEMS AND METHODS FOR TREATING SLEEP APNEA
IL200330A0 (en) Recombinant antibodies for treatment of respiratory syncytial virus infections
GB2496794B (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
ZA201209289B (en) Urea derivatives and their therapeutic use in the treatment of,inter alia,diseases of the respiratory tract
EP2427061A4 (en) GALLIUM FORMULATION FOR THE TREATMENT AND PROPHYLAXIS OF INFECTION DISEASES
EP2651439A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HUMAN ADENOVIRUS 36 INFECTION
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
GB2496800B (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
EP2521554A4 (en) SUBSTANCES AND METHODS FOR THE PREVENTION AND TREATMENT OF VIRAL INFECTIONS
HK1197058A1 (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
EP2222258A4 (en) SYSTEMS AND METHOD FOR HEAT TREATMENT OF BODY TISSUE
EP2361317A4 (en) USE OF EIF3M FOR THE DIAGNOSIS AND TREATMENT OF CANCER
PL2895180T3 (pl) Kompozycja do zapobiegania i leczenia ostrych i nawracających zakażeń dróg moczowych
SI2508192T1 (sl) Sredstvo za zdravljenje in preprečevanje bolezni moškega urogenitalnega sistema
HK1188565A1 (en) Diarylpyridazinone derivatives, preparation thereof, and use thereof for the treatment of humans
EP2160191A4 (en) SUPPRESSION OF VIRUSES INVOLVED IN A DISEASE OR RESPIRATORY INFECTION
SI2315580T1 (sl) Farmacevtski pripravki in postopki za zdravljenjeinfekcij respiratornega trakta
ZA201400442B (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease